p300/CREB-Binding Protein Enhances the Prolactin-Mediated Transcriptional Induction through Direct Interaction with the Transactivation Domain of Stat5, but Does Not Participate in the Stat5-Mediated Suppression of the Glucocorticoid Response
Edith Pfitzner,
Ruth Jähne,
Manuela Wissler,
Elisabeth Stoecklin and
Bernd Groner1
Institute for Experimental Cancer Research Tumor Biology
Center D-79106 Freiburg, Germany
 |
ABSTRACT
|
---|
Stat5 was discovered as a PRL-induced member of
the Stat (signal transducer and activator of transcription) family. Its
induction by many other cytokines and interleukins suggests that Stat5
plays a crucial role not only in mammary epithelial, but also in
hematopoietic cells. Cell type- and promoter- specific
functions of Stat5 are most likely modulated by the interaction with
other transcription factors. We recently showed cross-talk between
Stat5 and the glucocorticoid receptor. The activated glucocorticoid
receptor forms a complex with Stat5 and enhances Stat5-mediated
transcriptional induction. Conversely, Stat5 diminishes the induction
of glucocorticoid-responsive genes. Here, we investigated the role of
p300/CBP(CREB-binding protein), a transcriptional coactivator of
several groups of transcription factors, in Stat5-mediated
transactivation and in the cross-talk between Stat5 and the
glucocorticoid receptor. p300/CBP acts as a coactivator of Stat5. Its
ectopic expression enhances PRL-induced Stat5-mediated transcriptional
activation. Consistent with this observation, we find that the
adenovirus E1A protein, which binds to p300/CBP, suppresses
Stat5-induced transcriptional activation. This inhibition requires the
Stat5 transactivation domain and the p300/CBP binding site of E1A.
Coimmunoprecipitation and mammalian two-hybrid assays demonstrate a
direct interaction between the carboxyl-terminal transactivation domain
of Stat5 and p300/CBP. p300/CBP also positively interacts with the
glucocorticoid receptor and enhances glucocorticoid receptor-dependent
transcriptional activation of the mouse mammary tumor virus-long
terminal repeat promoter. Overexpression of p300/CBP does not
counteract the Stat5-mediated inhibition of glucocorticoid
receptor-dependent transactivation, i.e. the repression of
the glucocorticoid response by Stat5 is not a consequence of
competition for limiting amounts of p300/CBP.
 |
INTRODUCTION
|
---|
Studies on mammary epithelial cells have provided important
insights on the coordinate action of steroid and peptide hormones
(1, 2, 3). Milk protein gene expression in mammary epithelial cells is
regulated by the lactogenic hormones, PRL, insulin, and
glucocorticoids. The signal transduction pathways used by these
hormones and their interactions at the level of gene transcription have
been investigated (4, 5). Binding of PRL to its receptor at the cell
surface induces receptor dimerization and activation of the cytoplasmic
Janus kinase 2 (Jak2) (6, 7, 8). Jak2 phosphorylates and activates Stat5,
a transcription factor that belongs to the family of signal transducers
and activators of transcription (Stat) (8, 9, 10, 11). Phosphorylation
of tyrosine residue 694 causes Stat5 dimerization and confers specific
DNA-binding ability to promoter sequences in target genes. GAS-sites
(
-interferon activated sites) in the promoter or upstream enhancer
regions of several milk protein genes (ß-casein, ß-lactoglobulin,
and whey acidic protein) are required for maximal transcription during
lactation and PRL induction (12, 13, 14, 15).
Stat5, originally called mammary gland factor (MGF), was discovered as
a regulator of the ß-casein gene promoter that binds to the
ß-casein gene promoter GAS site (15) and was cloned from sheep tissue
as MGF/Stat5 (16). Two highly related Stat5 genes, Stat5a and Stat5b,
have been found in mouse and human DNA (17, 18, 19). The encoded proteins
are greater than 95% identical, form heterodimers after
phosphorylation and activation, and are both able to confer the PRL
response to the ß-casein gene promoter (18).
Glucocorticoids, in concert with PRL and insulin, induce the
transcription of the ß-casein gene in vivo and in HC11
mammary epithelial cells in vitro (20, 21). Glucocorticoids
act through the glucocorticoid receptor (GR), a member of the nuclear
receptor family of ligand-inducible transcription factors. Binding of
glucocorticoid hormone leads to activation of the latent receptor,
dimerization, nuclear translocation, specific DNA-binding to
glucocorticoid-response elements, and transcriptional activation
(22, 23). GR also acts as a negative transcriptional regulator and
cross-couples to other transcription factors like AP-1 (Jun/Fos) or
nuclear factor (NF)-
B (24, 25). Nuclear receptors must interact with
additional factors such as SRC-1, TRIP-1, RIP-140/160, TIF-1, SMART,
and N-CoR to mediate both activation and repression of gene expression
(26, 27).
The p300/CBP (CAAT-binding protein) proteins represent a family of
transcription coactivators that potentiate the activity of several
groups of transcription factors by interaction with their activated
forms (28, 29). This was originally observed for the protein kinase
A-activated form of CREB (cAMP response element-binding protein)
(30, 31, 32) and the adenovirus E1A protein (33) and has been extended to
other transcription factors (e.g. ATF, c-Jun, c-Fos, c-Myb,
Sap-1, tax, Myo D, P/CAF, SRC-1, NF-
B (28, 29). Most important for
the studies described here, p300/CBP has been shown to be a coactivator
of the GR and also of the interferon-
- and interferon-
-induced
members of the Stat family, Stat1 and Stat2 (34, 35, 36, 37). The different
Stat proteins (Stat1, 2, 3, 4, 5a, 5b, 6) are mainly related due to
their similar mode of action by various cytokines (10). Their sequence
homologies and functional relatedness are rather limited. Knock-out
mice, in which Stat1, Stat5a, or Stat5b have been inactivated, indicate
absolutely specialized functions for the different members of the Stat
family (38, 39, 40, 41). Sequence comparison showed that the carboxyl-terminal
transactivation domains are the most dissimilar parts of the different
Stat molecules (42). Various Stat proteins might therefore contact
distinct coactivators or members of the transcription machinery for
transcriptional activation. p300 and CBP are similar in sequence and
functionally interchangeable in most cases. p300 exhibits histone
acetyltransferase activity and associates with a protein with the same
enzymatic activity (P/CAF) (43, 44, 45). Accumulation of histone
acetyltransferase at specific genomic sites has been implicated in the
induction of gene expression through the remodeling of chromatin
structure (46, 47). CBP also plays a role in the negative cross-talk
between the GR and AP-1. Nuclear receptors, including the GR, interact
with CBP and inhibition of GR-mediated AP-1 activity results from
competition for limiting amounts of p300/CBP (35, 36).
The analysis of the mechanism by which PRL and glucocorticoid hormones
synergize in their transcriptional control has revealed a direct
interaction between Stat5 and the GR (48, 49). This interaction results
in an enhancement of Stat5-mediated transcriptional activation and an
inhibition of GR-dependent transcription. We further investigated the
molecular mechanisms of this transcription factor interaction and the
potential role of p300/CBP. Our results show that p300 directly
interacts with the transactivation domain of Stat5 and enhances
PRL-induced transcriptional activation. This can be observed with
Stat5, mStat5a, and mStat5b. Cytokine-activated, but not latent, Stat5
is able to interact with p300/CBP in vitro. The adenoviral
p300-binding protein E1A inhibits Stat5- mediated transcriptional
induction. The inhibition can be overcome by overexpression of p300. In
contrast, Stat5 inhibition of glucocorticoid-mediated transactivation
cannot be restored by overexpression of p300. These results indicate
that repression of the glucocorticoid response by Stat5 is not the
result of competition for limiting amounts of p300, but is most likely
due to the direct complex formation.
 |
RESULTS
|
---|
p300 Enhances PRL-Induced Transcription by MGF/Stat5, Mouse
(m)Stat5a, and mStat5b
p300, a protein with intrinsic histone acetylase activity, has
been found to be a crucial contributor to the activation of
transcription by diverse classes of exogenously regulated transcription
factors (29). Stat5 is a member of a gene family that regulates the
response to cytokines and was initially identified in the study of PRL
action. We have investigated the functional and physical interactions
between Stat5 and p300.
We have previously shown that heterologous cell systems, supplied with
the genes encoding the PRL receptor, Stat5, and a ß-casein
promoter-luciferase construct, can be used to study PRL-induced
signaling and transcription, normally restricted to mammary epithelial
cells. To investigate whether the p300 coactivator is involved in the
transcriptional regulation exerted by Stat5, HeLa cells were
transfected with expression vectors for the PRL receptor, MGF/Stat5,
and the ß-casein gene promoter-luciferase construct as a reporter.
The cells were treated with PRL, and luciferase activities were
measured. PRL treatment of the cells caused an approximately 5-fold
stimulation of the reporter gene (Fig. 1A
, lanes 1 and 2). Cotransfection of
increasing amounts of p300 increased the PRL-dependent transactivation
(lanes 3 to 8). p300 specifically enhanced the Stat5-induced
transcription; basal activity of the ß-casein promoter was not
affected.

View larger version (47K):
[in this window]
[in a new window]
|
Figure 1. p300 Enhances PRL-Induced, Stat5-Mediated
Transactivation
HeLa cells (A, C, and D) or 293 cells (B) were transfected with
expression vectors encoding MGF/Stat5 (Stat5) (A and B), mSTAT5a (C),
mStat5b (D), the PRL receptor (Prl R), and the ß-casein gene
promoter-luciferase reporter (ß-Cas-luc). The indicated amounts
(µg) of p300 were cotransfected. Transfected cells were either not
treated (solid bars) or treated for 14 h with 1
µg/ml PRL (hatched bars) as indicated. Cellular
extracts were prepared and luciferase activities were determined.
|
|
The induction-enhancing effect of p300 is not dependent on a specific
cell line. Consistent results were obtained in the
adenovirus-transformed human embryonic kidney cell line 293 (Fig. 1B
)
and COS7 cells (data not shown). Stat5 induction resulted in about an
18-fold stimulation of the reporter gene in 293 cells (Fig. 1B
, lanes 1
and 2). Increasing amounts of p300 further enhanced the PRL-induced
activity of the ß- casein reporter gene up to 120-fold (lanes
38).
Two closely related variants of Stat5 are encoded by the mouse genome
(mStat5a and mStat5b) (18). These proteins are greater than 95%
identical and differ mainly in their carboxyl-terminal transactivation
region. They can form homo- and heterodimers, and both variants are
able to confer the PRL response to the ß-casein gene promoter,
underlining their functional similarity (13, 18). MGF/Stat5, used in
the former experiments, is the sheep homolog of Stat5 and very similar
in sequence to mStat5a. To investigate whether p300 is involved in the
transcriptional regulation exerted by both variants of Stat5, HeLa
cells were transfected with ß-casein reporter plasmid and expression
vectors for the PRL receptor, Stat5a (Fig. 1C
), and Stat5b (Fig. 1D
).
Both Stat5 homologs stimulated the activity of the reporter gene about
6-fold (lanes 1 and 2). A p300 expression vector was included in the
transfection protocol (lanes 3 and 4). In the absence of PRL
stimulation of the cells, p300 expression did not affect basal
luciferase activity (lanes 3). Treatment with PRL caused a luciferase
induction. This induction was 2-fold higher in the p300-transfected
cells (lanes 4) when compared with the the controls (lanes 2). The
enhancement of PRL induction by p300 was observed for Stat5a as well as
for Stat5b.
E1A Inhibits PRL-Induced Transactivation by Stat5
The adenovirus E1A protein binds to p300 and CBP and inactivates
their function as coactivators of CREB-mediated transcription (50, 51).
The selective inhibition of p300 function allowed us to investigate
whether p300 is necessarily required for the PRL-induced
transactivation by Stat5. HeLa cells were transfected with expression
vectors for the PRL receptor, Stat5, and the ß-casein promoter
reporter construct. Treatment of the cells with PRL resulted in the
induction of luciferase activity (Fig. 2A
, lanes 1 and 2). Inclusion of an
expression vector for E1A in the transfection scheme resulted in the
suppression of PRL induction (lanes 3 and 4). This suppression was
overcome by the augmentation of p300 expression. Enhanced expression of
p300 not only restored PRL-induced transactivation, but resulted in
higher induction levels than in the control cells (compare lanes 2 and
8).

View larger version (22K):
[in this window]
[in a new window]
|
Figure 2. E1A Suppresses PRL-Induced Transactivation by Stat5
and p300 Restores Induction
HeLa cells were transfected with expression vectors encoding MGF/Stat5
(A and B), Stat5 750VP16 (C), the PRL receptor, and the
ß-casein-luciferase reporter gene. Expression plasmid (50 ng)
encoding E1A or the mutants thereof, CR1 and CR1, or the
indicated amount of p300 expression plasmid were cotransfected as
indicated. Transfected cells were either not treated (solid
bars) or treated for 14 h with 1 µg/ml PRL
(hatched bars). The schematic structures of E1A, CR1,
CR1, Stat5, and Stat5 750VP16 are shown. A, PRL-induced
transcriptional activation is repressed by E1A and restored by
exogenous expression of p300. B, The p300 but not the Rb binding
function of E1A is necessary for repression of Stat5-mediated
transcription. C, E1A inhibits transcriptional activation by Stat5, but
not by Stat5 750VP16.
|
|
We characterized the domains of E1A involved in the suppression of
Stat5- induced transcription. The deletion mutant
CR1 of E1A is
lacking the p300 and the Rb-binding functions; the mutant
CR2 lacks
the Rb-binding function, but retains its p300-binding function (52).
The structure of these molecules is schematically shown in Fig. 2
.
CR1 expression did not interfere with Stat5 induction of
transcription (Fig. 2B
, lanes 5 and 6), and
CR2 inhibited
PRL-induced transcription (lanes 7 and 8) to a similar extent as the
E1A wild-type molecule (lanes 1 and 2). A third variant of E1A, lacking
amino acids 6468 and unable to bind p300 but still able to bind Rb,
was tested. This variant did not affect PRL inducibility of the
reporter construct (data not shown). This indicates that the
p300-binding site within the E1A molecule is required for suppression
of Stat5-mediated transcription.
The Carboxyl-Terminal Transactivation Domain of Stat5 Is Required
for E1A-Dependent Suppression of Induction
We have previously reported that the transactivation domain of
Stat5 is located in the very carboxyl-terminal region. This
transactivation domain is autonomously active when fused to a
heterologous DNA-binding domain. The strength of the transactivation
domain was found to be weaker than those of Stat6 and VP16 (53).
Exchange of the Stat5 transactivation domain with that of VP16 resulted
in a molecule that retained its cytokine regulation, but which had a
stronger transactivation potential (53, 54). We investigated whether
the transactivation domain of Stat5 participates in the inhibitory
effect of E1A on the transcriptional activation. A molecule lacking the
endogenous transactivation domain of Stat5, but comprising the VP16
transactivation domain (Stat5
750VP16), was used for this
purpose.
PRL induction of cells transfected with Stat5
750VP16
leads to a much stronger transcriptional activation of the
ß-casein reporter (Fig. 2C
, lanes 1 and 2) compared with the
wild-type Stat5 (Fig. 2B
, lanes 1 and 2). Coexpression of E1A with
Stat5
750VP16 (Fig. 2C
, lanes 3 and 4),
CR1 (lanes 5 and 6), or
CR2 (lanes 7 and 8) did not interfere with the
transcriptional activation by Stat5
750VP16. Even a 10-fold increase
of E1A vector in the cotransfection scheme did not cause inhibition
(data not shown). These experiments show that E1A inhibition of
transcriptional activation is dependent upon the presence of the Stat5
transactivation domain and can be circumvented by the fusion of a
truncated Stat5 to the VP16 transactivation domain. These experiments
indicate that p300 acts as a coactivator of Stat5 through the
transactivation domain.
p300 Interacts with the Carboxyl-Terminal Transactivation Domain of
Stat5
Coactivators are thought to be transcription factors that
stabilize complexes between regulated activator proteins and the basal
transcription factors through direct protein-protein interactions (26).
Since p300 acts as a Stat5 coactivator, we investigated their potential
interaction in coimmunoprecipitation experiments. COS7 cells were
transfected with expression vectors encoding PRL receptor, Stat5, and
p300. Transfected cells were treated with PRL, nuclear extracts were
prepared, and proteins were immunoprecipitated with p300-specific
antibodies. The immunoprecipitates were analyzed by Western blotting
and developed with an antiserum specific to the carboxyl terminus
(lanes 13) or an antiserum specific for a more amino-terminal region
of Stat5 (lanes 47). The band in Fig. 3
, lane 2, indicates that the
p300-specific antiserum coimmunoprecipitates Stat5, most likely due to
a direct protein-protein interaction. When control antibodies, with
specificity for the yeast protein GAL4, were used in the
immunoprecipitation reaction, no Stat5 was detected (lane 3).

View larger version (21K):
[in this window]
[in a new window]
|
Figure 3. p300 Interacts with the Carboxyl-Terminal
Transactivation Domain of MGF/Stat5
A, Stat5 coimmunoprecipitates with p300. COS7 cells were transfected
with expression vectors encoding the PRL receptor, p300, and Stat5
(lanes 15) or with expression vectors encoding the PRL receptor,
p300, and Stat5 750. Cells were treated for 1 h with 1 µg/ml
PRL, and nuclear extracts were prepared. One-tenth of the nuclear
extracts were loaded directly onto a SDS/polyacrylamide gel (lanes 1,
4, and 6; input). The remainder was immunoprecipitated with
p300-specific antibodies (lanes 2, 5, and 7; -p300) or with
unrelated antibodies (lane 3; unrel.). All samples were analyzed by
Western blotting with an antiserum raised against the carboxyl terminus
of Stat5a (lanes 13; -Stat5C) or an antiserum raised amino acids
661677 of Stat5a (lanes 4 to 7; -Stat5N).
|
|
The suppression experiments shown in Fig. 2C
indicate that the
carboxyl-terminal region of Stat5 is involved in the p300 interaction.
To corroborate this conclusion, we performed immunoprecipitations from
nuclear extracts of cells transfected with Stat5
750, a variant in
which the carboxyl-terminal transactivation domain (amino acids
751794) of Stat5 has been deleted (55). Only a very weak band can be
detected in Fig. 3
(lane 7), indicating that the carboxyl-terminal
transactivation domain of Stat5 is necessary for the interaction with
p300.
A second, independent method was employed to confirm this conclusion, a
mammalian two-hybrid assay. For this purpose we fused the GAL4
DNA-binding domain (amino acids 1147) to the carboxyl-terminal
transactivation domain of Stat5 (amino acids 722794) (55). This
fusion construct (GAL4-Stat5TA) was cotransfected with a
Galp3TK-Luciferase into COS7 cells. The reporter construct
is regulated by three palindromic GAL4-binding sites and a minimal
thymidine kinase (TK) promoter. A 4-fold induction of transcription was
observed (Fig. 4
, lanes 1 and 2).
Addition of increasing amounts of a p300-VP16 expression vector,
encoding a p300 fused to the VP16 transactivation domain (56)
significantly enhanced the activity of the reporter gene (lanes 2- 5).
Transfection of p300-VP16 in the presence of a control vector, encoding
only the GAL4 DNA-binding domain (GAL4-DBD), had no affect on the
activity of the reporter construct (lanes 69). These results indicate
that the transactivation domain of Stat5 directly interacts with p300
and that the transactivation domain of Stat5 is necessary and
sufficient for this interaction.

View larger version (19K):
[in this window]
[in a new window]
|
Figure 4. p300 Interacts with the Carboxyl-Terminal
Transactivation Domain of Stat5 in the Mammalian Two-Hybrid Assay
The reporter plasmid Galp3TK-luciferase (2.5 µg) was
transfected in HeLa cells with plasmids expressing GAL4-Stat5TA (1
µg) or GAL4-DBD (1 µg) alone or in combination with increasing
amounts (0.5 to 6 µg) of expression vectors encoding p300-VP16.
Cellular extracts were prepared and luciferase activities were
determined.
|
|
To determine the domains of p300/CBP responsible for binding to Stat5,
individual fragments of CBP were expressed as
glutathione-S-transferase (GST) fusion proteins and tested
for their interaction with Stat5. We compared the binding capacity of
latent nonactivated Stat5 with that of the tyrosine-phosphorylated
activated form. The GST-CBP fusion proteins were expressed in bacteria,
bound to glutathione-Sepharose beads, and reacted with cell extracts
containing Stat5. Bound Stat5 was visualized upon gel electrophoresis
and Western blotting. The latent form of Stat5 was derived from
whole-cell extracts of HeLa cells, stably transfected with the PRL
receptor and Stat5a. The presence of Stat5 in this cellular extract is
shown in Fig. 5
(lane 1, upper
panel). No binding of latent Stat5 was observed to the GST-CBP
fusion molecules (lanes 27, upper panel). To investigate
whether phosphorylation and dimerization of Stat5 is necessary for the
interaction with p300/CBP, binding experiments were also performed with
whole-cell extracts from cells treated with PRL and containing the
activated form of Stat5. The fusion protein comprising the region of
CBP between amino acids 451 and 721 was found to interact with the
activated form of Stat5 (lane 3, lower panel). This
indicates that dimerization of Stat5 is required for the interaction
with the distinct part of p300/CBP and is consistent with our
coimmunoprecipitation experiments shown in Fig. 3
in which activated
Stat5 was present.

View larger version (39K):
[in this window]
[in a new window]
|
Figure 5. Activated Stat5a Interacts with the CREB-Binding
Domain of p300/CBP in Vitro
GST-fusion proteins of p300/CBP bound on glutathione-Sepharose beads
were incubated with whole-cell extracts from untreated (upper
panel) or PRL-treated (lower panel) HeLa cells
stably expressing the PRL receptor and Stat5a. Specifically bound
Stat5a was visualized by Western blotting using an anti-Stat5a
antibody.
|
|
Stat5 Represses Glucocorticoid Induction of the MMTV-LTR Promotor
in a Dose-Dependent Manner
Stat5, as shown above, and the GR both utilize p300 as a
coactivator (35, 36). We have investigated the effect of Stat5
activation on the induction of the GR-mediated transactivation of the
MMTV-LTR. MMTV-LTR contains a promoter region with several GR-binding
sites and responds to induction by glucocorticoid hormones (57). COS7
cells were transfected with expression vectors encoding the PRL
receptor, the GR, Stat5, and a MMTV-LTR luciferase reporter gene (Fig. 6
). In the absence of transfected GR, no
luciferase activity was detected, whether or not the cells were treated
with dexamethasone (lanes 13). A strong induction was observed when
the GR, but no Stat5, was transfected and the cells were induced with
dexamethasone (lanes 4 and 5) or dexamethasone plus PRL (lane 6).
Increasing amounts of Stat5 in the transfection scheme did not affect
dexamethasone inducibility of the MMTV-LTR as long as Stat5 was not
activated by PRL (lanes 8, 10, 12, 14, and 16). PRL addition to the
cells, i.e. Stat5 activation, suppressed the dexamethasone
inducibility of the MMTV-LTR in a Stat5 dose-dependent manner (lanes 9,
11, 13, 15, and 17). These results could be explained as the
consequence of competition of the GR and Stat5 for limiting amounts of
p300/CBP or by the interference of GR function through complex
formation with Stat5.

View larger version (37K):
[in this window]
[in a new window]
|
Figure 6. Stat5 Represses GR-Mediated Transcriptional
Activation in a Dose-Dependent Manner
COS7 cells were transfected with MMTV-LTR-luciferase reporter plasmid
(4 µg) and expression vectors encoding for the glucocorticoid
receptor (2 µg), the PRL receptor (250 ng), and increasing amounts of
Stat5 expression vector as indicated. Transfected cells were either not
treated or treated as indicated with 10-7 M
dexamethasone (open bars) and/or 5 µg/ml ovine PRL
(solid bars) for 16 h before harvesting.
|
|
Increased Expression of p300 Does Not Counteract Stat5-Mediated
Inhibition of GR Function
The simultaneous activation of Stat5 and the GR causes an
enhancement of the Stat5-dependent transcription of the ß-casein gene
promoter luciferase construct and a repression of the GR-mediated
induction of the MMTV-LTR luciferase construct (48). Since p300 is a
coactivator for both factors, we determined whether it is involved in
the repression process. We investigated the possibility that the
Stat5-mediated repression of the GR-induced transcription can be
compensated by the augmented expression of p300.
Introduction of the GR into COS7 cells resulted in the strong
inducibility of a MMTV-LTR luciferase reporter gene by dexamethasone
(Fig. 7
, lanes 1 and 2). Expression and
induction of Stat5 suppresses the MMTV-LTR luciferase induction (lanes
3 and 4). Addition of increasing amounts of p300 enhanced the
glucocorticoid-dependent transactivation in a dose- dependent
manner (lanes 5, 7, and 9). This indicates that endogenous p300
expression is limiting the extent of GR induction. The suppression of
dexamethasone induction of the MMTV-LTR by the activated Stat5 was not
relieved, however, by the increase in p300. Although the absolute
values of luciferase activity increased slightly in the presence of 5
µg and 10 µg of p300 vector in the transfection, the repression of
induction by activated Stat5 persisted (lanes 4, 6, 8, and 10). We
conclude that repression of GR-mediated induction by activated Stat 5
does not result from competition for limiting amounts of p300, a
mechanism suggested in the functional interaction between nuclear
receptors and AP-1 (35, 36). We propose that repression of GR function
by Stat5 is a consequence of their complex formation.

View larger version (27K):
[in this window]
[in a new window]
|
Figure 7. Increased Expression of p300 Does Not Counteract
Stat5-Mediated Repression of Glucocorticoid Induction of the MMTV-LTR
Promoter
COS7 cells were transfected with MMTV-LTR-luciferase reporter plasmid
(4 µg) and expression vectors encoding for the glucocorticoid
receptor (2 µg), the PRL receptor (250 ng), Stat5 (50 ng), and the
indicated amounts (µg) of p300 expression plasmids. Cells were either
untreated or treated as indicated with 10-7 M
dexamethasone (open bars) and/or 5 µg/ml ovine PRL
(solid bars).
|
|
Phosphorylation of Stat5 on Tyrosine 694, but Not the
Carboxyl-Terminal Transactivation Domain, Is Required for Inhibition of
GR Function
Specific phosphorylation of tyrosine 694 by Jak2 is essential for
the activation of Stat5 (13). It causes dimerization and nuclear
translocation of Stat5. We used a mutant of Stat5, in which tyrosine
694 was replaced by a phenylalanine residue and tested its ability to
repress transactivation of the MMTV-LTR by the GR. This mutant was not
able to repress GR transactivation (Fig. 8
, lanes 6 and 7). Activation of Stat5
through tyrosine phosphorylation is a necessary prerequisite for the
inhibitory effect. We also investigated whether the transactivation
domain of Stat5 participates in the inhibitory effect. A mutant lacking
the carboxyl-terminal transactivation domain, Stat5
750, inhibited
the glucocorticoid-induced transactivation of the MMTV-LTR reporter
plasmid as well as wild-type Stat5 (Fig. 8
; compare lanes 4 and 5 with
8 and 9). This result supports our finding that interaction of Stat5
with p300 is not involved in the repression process.

View larger version (39K):
[in this window]
[in a new window]
|
Figure 8. Stat5 Y 694 F, a Tyrosine Phosphorylation-Deficient
Variant of Stat5, Cannot Repress GR Function; Stat5 750, Lacking the
Transactivation Function, Represses GR-Mediated Transcription
Activation
COS 7 cells were transfected with MMTV-LTR luciferase reporter plasmids
(4 µg) and expression vectors encoding the GR (2 µg), the PRL
receptor (250 ng), Stat5, Stat5 Y694F, or Stat5 750 plasmids (50 ng
each). Cells were treated as indicated with 10-7
M dexamethasone (open bars) and/or 5 µg/ml
ovine PRL (solid bars).
|
|
 |
DISCUSSION
|
---|
Steroid and peptide hormones regulate specific gene transcription
through the activation of latent transcription factors. The
glucocorticoids are lipophilic hormones that enter the cell and bind to
their specific receptor in the cytoplasm. This leads to the activation,
dimerization, and DNA binding of the receptor and induction of target
genes (22). PRL binds to a trans-membrane receptor and induces its
dimerization and the activation of the associated kinase Jak2. Jak2
phosphorylates the receptor as well as signaling components,
e.g. Stat5. Tyrosine phosphorylation of Stat5 induces its
dimerization, translocation to the nucleus, specific DNA binding, and
induction of gene transcription (5).
A direct connection between the glucocorticoid- and PRL-induced signal
transduction pathways was recently found that involves complex
formation between the GR and Stat5 (48, 58, 59). This interaction
enhances PRL-induced Stat5-activated transcription, but suppresses
glucocorticoid-responsive transcriptional activation. We have further
investigated this interaction and examined the role of the coactivator
p300/CBP in the induction process. Members of the p300/CBP protein
family were originally detected through their ability to bind to E1A
and CREB (31, 33) and subsequently identified as coactivators for
nuclear hormone receptors (35, 36). p300/CBP act as integrators for
several signal transduction pathways (28, 29), e.g. they may
mediate the cross-talk between nuclear receptors and AP-1 (35, 36) and
connect IFN-
and Ras/AP-1 signaling (60).
We found that p300 enhances PRL-induced transcriptional acitvation by
Stat5a and Stat5b. These two variants of the Stat5 protein are encoded
by highly related genes and show a sequence identity of greater than
95% at the amino acid level. The most pronounced sequence
diversity is located in their carboxyl- terminal transactivation
region (18, 55), the region required for p300-mediated coactivation.
Both proteins can form homo- and heterodimers and are able to confer
the PRL response to the ß-casein gene promoter, i.e. they
are functionally very similar (13, 18). This is supported by our
finding that Stat5a and Stat5b, despite their sequence divergence in
the carboxyl-terminal region, can cooperate with p300.
The involvement of p300 in Stat5-induced transcription was confirmed in
experiments in which we observed that E1A inhibits Stat5-induced
transcriptional activation. E1A is thought to bind directly to p300 and
thereby prevents it from functioning as a coactivator of other
transcription factors (61), but E1A has also been shown to be able to
interact with other crucial cellular regulators such as the
transcriptional repressor Dr1, YY1, the general transcription factor
TBP, and Rb (62, 63, 64, 65). It also participates in the control of
transcription, DNA synthesis, and cell cycle regulation and
differentiation. Mutational analysis of the E1A protein has shown that
some activities of E1A are distinct from others and are carried out
independently by different regions of the protein (66). Our
observations that E1A-mediated inhibition of Stat5-induced
transcriptional activation can be overcome by overexpression of p300
and that inhibition by E1A requires the presence of an intact
p300-binding site of E1A indicate that the effect of E1A on Stat5
action is based on its physical interaction with p300.
293 cells are adenovirus transformed and express endogenous E1A. It
might have been anticipated that E1A expression would not allow
Stat5-mediated transactivation. In fact, we observed an 18-fold
induction of the ß-casein reporter gene. We conclude that the
residual, functional amounts of p300 are sufficient for transcriptional
activation by Stat5 (Fig. 1B
, lanes 1 and 2). Increasing amounts of
p300 further enhanced the PRL-induced activity of the ß-casein
reporter gene up to 120 fold (lanes 38). The higher induction in 293
cells as compared with HeLa cells might result from a modification of
p300 by E1A. An E1A-induced phosphorylation of p300 has been shown to
influence the interaction with transcription factors (DRF) and enhance
the induction of responsive promoters (67).
Our data might have interesting implications for the pathology of
adenovirus infections. If E1A expression, upon viral infection,
interferes with Stat5-induced transcription, processes dependent upon
crucial cytokines and growth factors, such as interleukin (IL)-2, IL-3,
IL-5, IL-7, IL-9, IL-10, IL-15, PRL, granulocyte-macrophage
colony-stimulating factor (GM-CSF), erythropoietin (EPO), GH, TPO, and
epidermal growth factor (EGF) might be affected. These cytokines have
been shown to exert at least part of their signaling potential through
the activation of Stat5 (17, 19, 68, 69, 70, 71, 72, 73, 74, 75, 76).
The inhibition of Stat5-induced transcription by E1A requires the Stat5
transactivation domain. Coimmunoprecipitation experiments and mammalian
two-hybrid assays revealed a direct interaction between p300 and Stat5.
Interactions between p300 and two other members of the STAT family,
Stat1 and Stat2, have recently been described, and the
carboxyl-terminal regions of Stat1 and Stat2 have been found to be
involved in those interactions (34, 37). In Stat1 there is an
additional contact region in the amino terminus (37). The
carboxyl-terminal regions of Stat1 and Stat2 both function as
transactivation domains, but are distinct in character. The carboxyl
terminus of Stat2, a highly acidic region, does not undergo serine
phosphorylation. The carboxyl- terminal transactivation domain of Stat5
could form an amphipathic
-helix with clusters of acidic residues on
one face and hydrophobic residues on the other (55). Despite these
differences, p300 acts as a coactivator for all three Stat factors.
Our observation that p300 is a coactivator of Stat5 reveals at least
three interesting protein-protein interactions in the lactogenic
hormone scheme: p300 interacts with Stat5 and the GR; Stat5 and the GR
interact with each other. Since the GR enhances Stat5 action at the
level of the ß-casein gene promoter and Stat5 antagonizes the GR at
the level of the MMTV-LTR, we analyzed the effect of p300 on
Stat5-mediated repression on glucocorticoid response. p300 enhances the
GR-dependent transcriptional activation of the MMTV-LTR in the absence
of activated Stat5, but does not counteract Stat5-mediated repression
of induction. Analysis of Stat5 variants in transfection assays
indicate that the activation of Stat5 through tyrosine phosphorylation
is required for the repression of Stat5 on GR function. However, the
transactivation domain of Stat5, which is also the domain responsible
for the interaction with p300/CBP, is not required. Competition for
p300 has been invoked in the interaction between Stat1 and AP-1 (60)
and is probably also responsible for the E1A inhibition of Stat5
transactivation described here. Repression of GR transactivation by
Stat 5, however, is not the consequence of competition for limiting
amounts of p300, but most likely results from the complex formation
between the two transcription factors.
Complex formation between Stat5 and the GR has been observed in COS7
cells overexpressing GR and Stat5 (48) but also in HC11 mammary
epithelial cells expressing physiological levels of GR and Stat5 (59).
Decreased binding of the GR to glucocorticoid- response elements in
the presence of activated Stat5 might be a possible mechanism for
repression. This, however, could not be observed in in vitro
bandshift experiments with extracts from transfected cells (data not
shown). A further possible mechanism for the Stat5-mediated inhibition
of the GR transactivation function is that a complex of Stat5 and GR
might cause sterical hindrance and interfere with contacts between the
GR and coactivators or the basal transcription machinery. It will be of
interest to investigate whether complex formation between GR and Stat5
also influences the transrepression function of the GR on AP-1 and
NF-
B-responsive genes. p300/CBP seems to be an important integrator
in these different signaling pathways involved in inflammation reaction
and immune response. The observed negative cross-talk of Stat5 on GR
function might also have implications for T lymphocyte development and
differentiation as well as in erythropoiesis. GR is thought to control
thymocyte apoptosis and proliferation of erythroblasts (77).
GR activation has a synergistic effect on the transcription of the
ß-casein gene promoter activated by Stat5 (48). When p300 was added,
a further increase in transcription, above the GR-mediated effect, was
observed (not shown). These results indicate that the GR/Stat5 complex
recruits high levels of p300. The ß-casein reporter construct used in
our experiments contains, in addition to the Stat5-binding sites,
several binding sites for regulator proteins such as C/EBP and YY1
(15). C/EBPß has been shown to interact and collaborate with p300,
and relief of YY1 transcriptional repression has been described to be
mediated by p300 (78, 79). This indicates that there are several
contact sites for p300 in the ß-casein promoter and that p300 might
coordinate the cooperation between different regulatory factors that
bind to the ß-casein promoter. The recruitment of this coactivator
and its associated histone acetyl transferase activity may result in a
chromatin configuration that allows the efficient assembly and enhanced
stabilization of the preinitiation complex, and its local concentration
may eventually determine the extent of transcriptional induction.
 |
MATERIALS AND METHODS
|
---|
Plasmids
The ß-casein gene promoter (-344 to -1) luciferase construct
and the expression vectors for sheep MGF/Stat5 (pXM-MGF), mStat5a
(pXM-Stat5a), mStat5b (pXM-Stat5b), the deletion mutant Stat5
750
(pXM-MGF
750), the point mutant Stat5 Y694F (pXM-MGF Y694F), and the
long form of the PRL receptor (pcDNAI-PrlR) were described previously
(13, 16, 55). To construct Stat5
750VP16, the transactivation domain
of VP16 (amino acids 411489) was amplified by PCR and fused in frame
to the 3'-end of pXM-MGF
750 (53). The human GR expression vector
pRSVhGRa (GR) (80), the MMTV-LTR-luciferase reporter (81), and the
expression vectors for pCMV (cytomegalovirus promoter
enhancer)-p300 and p300-VP16 have been described (33, 56). The
same is true for the RSV LTR (Rous sarcoma virus long terminal
repeat)-E1A 12S constructs and the mutants E1A
CR1 and E1A
CR2
(52), and the reporter plasmid Galp3TK-luciferase, which
contains three copies of the UASG cloned upstream of the TK
promoter (82). The plasmids encoding the GAL4-Stat5TA fusion comprise
the DNA-binding and dimerization domains of yeast GAL4 protein (amino
acids 1147) and the carboxyl-terminal transactivation domain of Stat5
(amino acids 722794). GAL4-DBD and GAL4-Stat5TA have been described
previously (55).
Cell Culture and Transfection
HeLa cells, 293 cells, and COS7 cells were maintained in DMEM
containing 10% FCS, 2 mM glutamine, and 50 µg/ml
gentamycin. Transient transfection experiments were performed using the
calcium phosphate precipitation technique (13). Half-confluent cells in
10-cm dishes were cotransfected with the ß-casein luciferase reporter
constructs (2 µg) and expression vectors for Stat5 (2 µg) or its
variants, the PRL receptor (250 ng), and p300 or E1A expression
plasmids, as indicated in the figure legends. To monitor the
GR-dependent transcriptional activation, the MMTV-LTR-luciferase
reporter construct (4 µg) was cotransfected with an expression vector
encoding the GR (2 µg), the PRL receptor (250 ng), and the indicated
amounts of Stat5 and p300. Plasmid (0.5 µg) encoding the
ß-galactosidase gene driven by the CMV promoter was included to
monitor transfection efficiency. The DNA was adjusted to 10 µg with
empty vector-DNA. One day after transfection, the cells were treated
with 5 µg/ml ovine PRL and/or 10-7 M
dexamethasone for 16 h before harvesting.
Luciferase and ß-Galactosidase Assays
Two days after transfection cells were harvested, washed twice
in cold PBS, and lysed in 25 mM glycylglycine, pH 7.8, 1
mM dithiothreitol (DTT), 15 mM
MgSO4, 4 mM EGTA, and 1% Triton for 10 min at
4 C. Samples were centrifuged for 5 min at 14,000 rpm. Cleared
supernatants were used for luciferase and ß-galactosidase assays. For
ß-galactosidase determination, 20 µl of extracts were added to 200
µl of reaction buffer containing 100 mM Na-phosphate, pH
8.0, 1 mM MgCl2, and 1 x Galacton
(Tropix, Bedford, MA) and incubated for 30 min at room temperature.
Measurements were made by injecting 300 µl of accelerator solution
(10% Emerald luminescent amplifier and 0.2 N NaOH), and the samples
were counted for 20 sec in the Luminometer 953 (Berthold, Pforzheim,
Germany). Luciferase activities (100 µl extracts and 300 µl
accelerator solution) were quantified in the same apparatus and
normalized to the ß-galactosidase activities. At least three
independent experiments were performed.
Coimmunoprecipitation Assay
COS7 cells were transfected with expression plasmids encoding
Stat5 or Stat5
750, p300, and the PRL receptor. One day after
transfection, the cells were treated with 5 µg/ml ovine PRL for
1 h before harvesting. Nuclear extracts from the induced cells
were prepared. Protein (200 µg) was incubated with 4 µg of
p300-specific monoclonal antibodies (Upstate Biotechnology, Lake
Placid, NY) or as a control, with antibodies against the GAL4
DNA-binding domain (Santa Cruz Biotechnology, Santa Cruz) overnight at
4 C at constant agitation. Protein A/G-Sepharose-coupled beads
(Pierce, Rockford, IL) were added for 1 h. The beads were
pelleted and washed five times with incubation buffer (20
mM HEPES,pH 7.9, 100 mM NaCl, 10 mM
KCl, 0.1 mM NaVO4, 1 mM EDTA, 1
mM DTT). The immunoprecipitates were separated by SDS-PAGE,
and the Western blots were developed with antiserum specific against
the carboxyl terminus of Stat5a (
Stat5C) or an antiserum against
amino acids 661677 of Stat5a (
Stat5N).
Mammalian Two-Hybrid Assay
Half-confluent HeLa cells in 10-cm dishes were cotransfected
with the reporter plasmid Galp3TK-luciferase (2.5 µg) and
expression vectors for GAL4-Stat5TA (1 µg), the GAL4-DBD (1 µg),
and p300-VP16. Plasmid (0.5 µg) encoding the ß-galactosidase gene
driven by the CMV promoter was included to monitor transfection
efficiency. Luciferase assays were performed as described.
GST-Fusion Protein Interaction Assay and Western Blot
Analysis
The expression vectors for the GST-CBP fusion proteins have been
described previously (83). GST-fusion proteins were purified from
bacterial extracts using glutathione-Sepharose beads as specified by
the manufacturer (Pharmacia, Freiburg, Germany). Whole-cell extracts
from HeLa cells stably expressing the PRL receptor and Stat5a were
prepared as described previously (13). The cells were either untreated,
to obtain the latent form of Stat5a, or treated with 5 µg/ml ovine
PRL for 1 h before harvesting, to obtain the activated form of
Stat5a. For binding assays, 150 µg protein from whole-cell extracts
were incubated with 1020 µg of GST-fusion proteins bound on beads
at 4 C for 1 h under constant agitation in 500 µl 50
mM Tris-HCl (pH 8), 100 mM NaCl, 0,3
mM DTT, 10 mM MgCl2, 10% glycerol
and 0,1% Nonidet P-40 (NP40). The protein complexes were washed five
times in binding buffer. The bound proteins were eluted from the beads
with SDS sample buffer and analyzed by SDS-PAGE. Western blot analyses
were done using the antiserum specific against the carboxyl terminus of
Stat5a.
 |
ACKNOWLEDGMENTS
|
---|
We thank R. Eckner (Zürich, Switzerland) and T. Kouzarides
(Cambridge, U.K.) for plasmids and reagents; C. Beisenherz, M. Frische,
R. Moriggl, B. Schnierle, and C. Shemanko (Freiburg, Germany) for
discussions and critical reading of the manuscript; and I. Fernandez
for editorial assistance.
 |
FOOTNOTES
|
---|
1 Address requests for reprints to: Dr. Bernd Groner, Institute for
Experimental Cancer Research, Tumor Biology Center Freiburg, Breisacher
Strasse 117, D-79106 Freiburg, Germany. 
Received for publication January 30, 1998.
Revision received June 4, 1998.
Accepted for publication July 2, 1998.
 |
REFERENCES
|
---|
-
Imagawa W, Yang J, Guzman R, Nandi S 1994 Control of
mammary gland development. In: Knobil E, Neill JD (eds) The Physiology
of Reproduction. Raven Press, New York, pp 10331065
-
Neville MC, Daniel CW (eds) 1987 The Mammary Gland:
Development, Regulation, and Function. Plenum Press, New York
-
Topper YJ, Freeman CS 1980 Multiple hormone interactions in
the developmental biology of the mammary gland. Physiol Rev 60:10491106[Free Full Text]
-
Groner B, Altiok S, Meier V 1994 Hormonal regulation of
transcription factor activity in mammary epithelial cells. Mol Cell
Endocrinol 100:109114[CrossRef][Medline]
-
Groner B, Gouilleux F 1995 Prolactin-mediated gene activation
in mammary epithelial cells. Curr Opin Genet Dev 5:587594[CrossRef][Medline]
-
Darnell Jr JE, Kerr IM, Stark GR 1994 Jak-STAT pathways and
transcriptional activation in response to IFNs and other extracellular
signaling proteins. Science 264:14151421[Medline]
-
Kelly PA, Djiane J, Postel-Vinay MC, Edery M 1991 The
prolactin/growth hormone receptor family. Endocr Rev 12:235251[Abstract]
-
Schindler C, Darnell Jr JE 1995 Transcriptional responses to
polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64:621651[CrossRef][Medline]
-
Ihle JN, Kerr IM 1995 Jaks and Stats in signaling by the
cytokine receptor superfamily. Trends Genet 11:6974[CrossRef][Medline]
-
Ihle JN 1996 STATs: signal transducers and activators of
transcription. Cell 84:331334[Medline]
-
Pellegrini S, Dusanter-Fourt I 1997 The structure, regulation
and function of the Janus kinases (JAKs) and the signal transducers and
activators of transcription (STATs). Eur J Biochem 248:615633[Abstract]
-
Burdon T, Sankaran L, Wall RJ, Spencer M, Hennighausen L 1991 Expression of a whey acidic protein transgene during mammary
development. Evidence for different mechanisms of regulation during
pregnancy and lactation. J Biol Chem 266:69096914[Abstract/Free Full Text]
-
Gouilleux F, Wakao H, Mundt M, Groner B 1994 Prolactin induces
phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA
binding and induction of transcription. EMBO J 13:43614369[Abstract]
-
Li S, Rosen JM 1995 Nuclear factor I and mammary gland factor
(STAT5) play a critical role in regulating rat whey acidic protein gene
expression in transgenic mice. Mol Cell Biol 15:20632070[Abstract]
-
Schmitt-Ney M, Doppler W, Ball RK, Groner B 1991 Beta-casein
gene promoter activity is regulated by the hormone-mediated relief of
transcriptional repression and a mammary-gland-specific nuclear factor.
Mol Cell Biol 11:37453755[Medline]
-
Wakao H, Gouilleux F, Groner B 1994 Mammary gland factor (MGF)
is a novel member of the cytokine regulated transcription factor gene
family and confers the prolactin response [published erratum appears
in EMBO J 1995 Feb 15;14(4):8545]. EMBO J 13:21822191[Abstract]
-
Azam M, Erdjument-Bromage H, Kreider BL, Xia M, Quelle F, Basu
R, Saris C, Tempst P, Ihle JN, Schindler C 1995 Interleukin-3 signals
through multiple isoforms of Stat5. EMBO J 14:14021411[Abstract]
-
Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L 1995 Cloning and expression of Stat5 and an additional homologue (Stat5b)
involved in prolactin signal transduction in mouse mammary tissue. Proc
Natl Acad Sci USA 92:88318835[Abstract]
-
Mui AL, Wakao H, OFarrell AM, Harada N, Miyajima A 1995 Interleukin-3, granulocyte-macrophage colony stimulating factor
and interleukin-5 transduce signals through two STAT5 homologs. EMBO J 14:11661175[Abstract]
-
Ball RK, Friis RR, Schoenenberger CA, Doppler W, Groner B 1988 Prolactin regulation of beta-casein gene expression and of a cytosolic
120-kd protein in a cloned mouse mammary epithelial cell line. EMBO J 7:20892095[Abstract]
-
Doppler W, Groner B, Ball RK 1989 Prolactin and glucocorticoid
hormones synergistically induce expression of transfected rat
beta-casein gene promoter constructs in a mammary epithelial cell line.
Proc Natl Acad Sci USA 86:104108[Abstract]
-
Beato M, Herrlich P, Schutz G 1995 Steroid hormone receptors:
many actors in search of a plot. Cell 83:851857[Medline]
-
Mangelsdorf DJ, Thummel C, Beato M, Herrlich PZ, Schutz G,
Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans RM 1995 The nuclear receptor superfamily: the second decade. Cell 83:835839[Medline]
-
Cato AC, Wade E 1996 Molecular mechanisms of anti-inflammatory
action of glucocorticoids. Bioessays 18:371378[Medline]
-
Ponta H, Cato AC, Herrlich P 1992 Interference of pathway
specific transcription factors. Biochim Biophys Acta 1129:255261[Medline]
-
Horwitz KB, Jackson TA, Bain DL, Richer JK, Takimoto GS, Tung
L 1996 Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:11671177[Abstract]
-
McEwan IJ, Wright AP, Gustafsson JA 1997 Mechanism of gene
expression by the glucocorticoid receptor: role of protein-protein
interactions. Bioessays 19:153160[Medline]
-
Eckner R 1996 p300 and CBP as transcriptional regulators and
targets of oncogenic events. Biol Chem 377:685688
-
Janknecht R, Hunter T 1996 Transcription. A growing
coactivator network. Nature 383:2223[CrossRef][Medline]
-
Arias J, Alberts AS, Brindle P, Claret FX, Smeal T, Karin M,
Feramisco J, Montminy M 1994 Activation of cAMP and mitogen responsive
genes relies on a common nuclear factor. Nature 370:226229[CrossRef][Medline]
-
Chrivia JC, Kwok RP, Lamb N, Hagiwara M, Montminy MR, Goodman
RH 1993 Phosphorylated CREB binds specifically to the nuclear protein
CBP. Nature 365:855859[CrossRef][Medline]
-
Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP,
Brennan RG, Roberts SG, Green MR, Goodman RH 1994 Nuclear protein CBP
is a coactivator for the transcription factor CREB. Nature 370:223226[CrossRef][Medline]
-
Eckner R, Ewen ME, Newsome D, Gerdes M, DeCaprio JA, Lawrence
JB, Livingston DM 1994 Molecular cloning and functional analysis of the
adenovirus E1A-associated 300-kD protein (p300) reveals a protein with
properties of a transcriptional adaptor. Genes Dev 8:869884[Abstract]
-
Bhattacharya S, Eckner R, Grossman S, Oldread E, Arany Z,
DAndrea A, Livingston DM 1996 Cooperation of Stat2 and
p300/CBP in signalling induced by interferon-alpha. Nature 383:344347[CrossRef][Medline]
-
Chakravarti D, La Morte VJ, Nelson MC, Nakajima T, Schulman
IG, Juguilon H, Montminy M, Evans RM 1996 Role of CBP/P300 in nuclear
receptor signalling [see comments]. Nature 383:99103[CrossRef][Medline]
-
Kamei Y, Xu L, Heinzel t, Torchia J, Kurokawa R, Gloss B, Lin
SC, Heyman RA, Rose DW, Glass CK, Rosenfeld MG 1996 A CBP integrator
complex mediates transcriptional activation and AP-1 inhibition by
nuclear receptors. Cell 85:403414[Medline]
-
Zhang JJ, Vinkemeier U, Gu W, Chakravarti D, Horvath CM,
Darnell Jr JE 1996 Two contact regions between Stat1 and CBP/p300 in
interferon gamma signaling. Proc Natl Acad Sci USA 93:1509215096[Abstract/Free Full Text]
-
Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS,
Kaplan DH, Riley JK, Greenlund AC, Campbell D, Carver-Moore K, DuBois
RN, Clark R, Aguet M, Schreiber RD 1996 Targeted disruption of the
Stat1 gene in mice reveals unexpected physiologic specificity in the
JAK-STAT signaling pathway. Cell 84:431442[Medline]
-
Durbin JE, Hackenmiller R, Simon MC, Levy DE 1996 Targeted
disruption of the mouse Stat1 gene results in compromised innate
immunity to viral disease. Cell 84:443450[Medline]
-
Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A,
Hennighausen L 1997 Stat5a is mandatory for adult mammary gland
development and lactogenesis. Genes Dev 11:179186[Abstract]
-
Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA,
Waxman DJ, Davey HW 1997 Requirement of STAT5b for sexual dimorphism of
body growth rates and liver gene expression. Proc Natl Acad Sci USA 94:72397244[Abstract/Free Full Text]
-
Darnell Jr JE 1997 STATs and gene regulation. Science 277:16301635[Abstract/Free Full Text]
-
Bannister AJ, Kouzarides T 1996 The CBP co-activator is a
histone acetyltransferase. Nature 384:641643[CrossRef][Medline]
-
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y 1996 The transcriptional coactivators p300 and CBP are histone
acetyltransferases. Cell 87:953959[Medline]
-
Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y 1996 A
p300/CBP-associated factor that competes with the adenoviral
oncoprotein E1A. Nature 382:319324[CrossRef][Medline]
-
Jenster G, Spencer TE, Burcin MM, Tsai SY, Tsai MJ, OMalley,
BW 1997 Steroid receptor induction of gene transcription: a two-step
model. Proc Natl Acad Sci USA 94:78797884[Abstract/Free Full Text]
-
Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK,
Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and
mediates nuclear- receptor function [see comments]. Nature 387:677684[CrossRef][Medline]
-
Stoecklin E, Wissler M, Gouilleux F, Groner B 1996 Functional
interactions between Stat5 and the glucocorticoid receptor. Nature 383:726728[CrossRef][Medline]
-
Stoecklin E, Wissler M, Moriggl R, Groner B 1997 Specific DNA
binding of Stat5, but not of glucocorticoid receptor, is required for
their functional cooperation in the regulation of gene transcription.
Mol Cell Biol 17:67086716[Abstract]
-
Arany Z, Newsome D, Oldread E, Livingston DM, Eckner R 1995 A
family of transcriptional adaptor proteins targeted by the E1A
oncoprotein. Nature 374:8184[CrossRef][Medline]
-
Lundblad JR, Kwok RP, Laurance ME, Harter ML, Goodman RH 1995 Adenoviral E1A-associated protein p300 as a functional homologue of the
transcriptional co-activator CBP. Nature 374:8588[CrossRef][Medline]
-
Bannister AJ, Kouzarides T 1995 CBP-induced stimulation of
c-Fos activity is abrogated by E1A. EMBO J 14:47584762[Abstract]
-
Moriggl R, Berchtold S, Freidrich K, Standke GJ, Kammer W,
Heim M, Wissler M, Stocklin E, Gouilleux F, Groner B 1997 Comparison of
the transactivation domains of Stat5 and Stat6 in lymphoid cells and
mammary epithelial cells. Mol Cell Biol 17:36633678[Abstract]
-
Berchtold S, Moriggl R, Gouilleux F, Silvennoinen O,
Beisenherz C, Pfitzner E, Wissler M, Stocklin E, Groner B 1997 Cytokine
receptor-independent, constitutively active variants of STAT5 [In
Process Citation]. J Biol Chem 272:3023730243[Abstract/Free Full Text]
-
Moriggl R, gouilleux-Gruart V, Jahne R, Berchtold S, Gartmann
C, Liu X, Hennighausen L, Sotiropoulos A, Groner B, Gouilleux F 1996 Deletion of the carboxyl-terminal transactivation domain of MGF-Stat5
results in sustained DNA binding and a dominant negative phenotype. Mol
Cell Biol 16:56915700[Abstract]
-
Eckner R, Yao TP, Oldread E, Livingston DM 1996 Interaction
and functional collaboration of p300/CBP and bHLH proteins in muscle
and B-cell differentiation. Genes Dev 10:24782490[Abstract]
-
Hynes NE, Kennedy N, Rahmsdorf U, Groner B 1981 Hormone-responsive expression of an endogenous proviral gene of mouse
mammary tumor virus after molecular cloning and gene transfer into
cultured cells. Proc Natl Acad Sci USA 78:20382042[Abstract]
-
Lechner J, Welte T, Tomasi JK, Bruno P, Cairns C, Gustafsson
J, Doppler W 1997 Promoter-dependent synergy between glucocorticoid
receptor and Stat5 in the activation of beta-casein gene transcription.
J Biol Chem 272:2095420960[Abstract/Free Full Text]
-
Cella N, Groner B, Hynes NE 1998 Characterization of Stat5a
and Stat5b homodimers and heterodimers and their association with the
glucocortiocoid receptor in mammary cells. Mol Cell Biol 18:17831792[Abstract/Free Full Text]
-
Horvai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen TM, Rose
DW, Rosenfeld MG, Glass CK 1997 Nuclear integration of JAK/STAT and
Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA 94:10741079[Abstract/Free Full Text]
-
Lee JS, See RH, Deng T, Shi Y 1996 Adenovirus E1A
downregulates cJun- and JunB-mediated transcription by targeting their
coactivator p300. Mol Cell Biol 16:43124326[Abstract]
-
Lee WS, Kao CC, Bryant GO, Liu X, Berk AJ 1991 Adenovirus E1A
activation domain binds the basic repeat in the TATA box transcription
factor. Cell 67:365376[Medline]
-
Dyson N, Guida P, Munger K, Harlow E 1992 Homologous sequences
in adenovirus E1A and human papillomavirus E7 proteins mediate
interaction with the same set of cellular proteins. J Virol 66:68936902[Abstract]
-
Kraus VB, Inostroza JA, Yeung K, Reinberg D, Nevins JR 1994 Interaction of the Dr1 inhibitory factor with the TATA binding protein
is disrupted by adenovirus E1A. Proc Natl Acad Sci USA 91:62796282[Abstract]
-
Lewis BA, Tullis G, Seto E, Horikoshi N, Weinmann R, Shenk T 1995 Adenovirus E1A proteins interact with the cellular YY1
transcription factor. J Virol 69:16281636[Abstract]
-
Whyte P, Williamson NM, Harlow E 1989 Cellular targets for
transformation by the adenovirus E1A proteins. Cell 56:6775[Medline]
-
Kitabayashi I, Eckner R, Arany Z, Chiu R, Gachelin G,
Livingston DM, Yokoyama KK 1995 Phosphorylation of the adenovirus
E1A-associated 300 kDa protein in response to retinoic acid and E1A
during the differentiation of F9 cells. EMBO J 14:34963509[Abstract]
-
Gouilleux F, Moritz D, Humar M, Moriggl R, Berchtold S, Groner
B 1995 Prolactin and interleukin-2 receptors in T lymphocytes signal
through a MGF-STAT5-like transcription factor. Endocrinology 136:57005708[Abstract]
-
Gouilleux F, Pallard C, Dusanter-fourt I, Wakao H, Haldosen
LA, Norstedt G, Levy D, Groner B 1995 Prolactin, growth hormone,
erythropoietin and granulocyte-macrophage colony stimulating factor
induce MGF-Stat5 DNA binding activity. EMBO J 14:20052013[Abstract]
-
Ihle JN 1996 Signaling by the cytokine receptor superfamily in
normal and transformed hematopoietic cells. Adv Cancer Res 68:2365[Medline]
-
Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, Shibuya
K, Ortaldo JR, Gupta S, Chen YQ, Giri JD, OShea JJ 1995 Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus
kinases by interleukins 2 and 15. Proc Natl Acad Sci USA 92:87058709[Abstract]
-
Lin JX, Migone TS, Tsang M, Freidmann M, Weatherbee JA, Zhou
L, Yamauchi A, Bloom ET, Mietz J, John S, Leonard WJ 1995 The
role of shared receptor motifs and common Stat proteins in the
generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7,
IL-13, and IL-15. Immunity 2:331339[Medline]
-
Pallard C, Gouilleux F, Charon M, Groner B, Gisselbrecht S,
Dusanter-Fourt I 1995 Interleukin-3, erythropoietin, and prolactin
activate a STAT5-like factor in lymphoid cells. J Biol Chem 270:1594215945[Abstract/Free Full Text]
-
Ruff-Jamison S, Chen K, Cohen S 1995 Epidermal growth factor
induces the tyrosine phosphorylation and nuclear translocation of Stat
5 in mouse liver. Proc Natl Acad Sci USA 92:42154218[Abstract]
-
Wakao H, Harada N, Kitamura T, Mui AL, Miyajima A 1995 Interleukin 2 and erythropoietin activate STAT5/MGF via distinct
pathways. EMBO J 14:25272535[Abstract]
-
Wood TJ, Silva D, Lobie PE, Pircher TJ, Gouilleux f, Wakao H,
gustafsson JA, Groner B, Norstedt G, Haldosen LA 1995 Mediation of
growth hormone-dependent transcriptional activation by mammary gland
factor/Stat 5. J Biol Chem 270:94489453[Abstract/Free Full Text]
-
Reichardt HM, Kaestner KH, Tuckermanm J, Kretz O, Wessely O,
Bock R, Gass P, Schmid W, Herrlich P, Angel P, Schutz G 1998 DNA
binding of the glucocorticoid receptor is not essential for survival.
Cell 93:531541[Medline]
-
Mink S, Haenig B, Klempnauer KH 1997 Interaction and
functional collaboration of p300 and C/EBPbeta. Mol Cell Biol 17:66096617[Abstract]
-
Lee JS, Galvin KM, See RH, Eckner R, Livingston D, Moran E,
Shi Y 1995 Relief of YY1 transcriptional repression by adenovirus E1A
is mediated by E1A-associated protein p300 [published erratum appears
in Genes Dev 1995 Aug 1;9(15):19489]. Genes Dev 9:11881198[Abstract]
-
Giguere V, Hollenberg SM, Rosenfeld MG, Evans RM 1986 Functional domains of the human glucocorticoid receptor. Cell 46:645652[Medline]
-
Gouilleux F, Sola B, Couette B, Richard-Foy H 1991 Cooperation
between structural elements in hormone-regulated transcription from the
mouse mammary tumor virus promoter. Nucleic Acids Res 19:15631569[Abstract]
-
Forman BM, Umesono K, Chen J, Evans RM 1995 Unique response
pathways are established by allosteric interactions among nuclear
hormone receptors. Cell 81:541550[Medline]
-
Janknecht R, Nordheim A 1996 Regulation of the c-fos promoter
by the ternary complex factor Sap-1a and its coactivator CBP. Oncogene 12:19611969[Medline]